Persistent change in cardiac fibroblast physiology after transient ACE inhibition

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 309, Issue 8, 2015, Pages H1346-H1353

  D'Souza K M ^a   Biwer, L A ^a   Madhavpeddi, L ^a   Ramaiah, P ^a   Shahid, W ^a   Hale, T M ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Angiotensin converting enzyme inhibitor; Cardiac fibroblast; Collagen; Inflammation; Proliferation

Indexed keywords

BETA ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; AUTACOID; CCL2 PROTEIN, RAT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARDITIS; CELL PROLIFERATION; CELL SELECTION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART FIBROBLAST; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; IN VITRO STUDY; MALE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; YOUNG ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOMYOPATHIES; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; FIBROBLAST; FIBROSIS; GENETICS; HEART VENTRICLE; HYPERTENSION; METABOLISM; PATHOLOGY; PHENOTYPE; SPONTANEOUSLY HYPERTENSIVE RAT; TIME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOMYOPATHIES; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL2; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; ENALAPRIL; FIBROBLASTS; FIBROSIS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEART VENTRICLES; HYPERTENSION; INFLAMMATION MEDIATORS; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PHENOTYPE; RATS, INBRED SHR; TIME FACTORS;

EID: 84944402073     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00615.2015     Document Type: Article

References (39)

1. Akashiba A, Ono H, Ono Y, Ishimitsu T, Matsuoka H. Valsartan improves L-NAME-exacerbated cardiac fibrosis with TGF-inhibition and apoptosis induction in spontaneously hypertensive rats. J Cardiol 52: 239-246, 2008.
2. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 117: 568-575, 2007.
3. Biwer LA, Broderick TL, Xu H, Carroll C, Hale TM. Protection against L-NAME-induced reduction in cardiac output persists even after cessation of angiotensin-converting enzyme inhibitor treatment. Acta Physiol (Oxf) 207: 156-165, 2013.
4. Brilla CG. Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs. Cardiovasc Res 46: 324-331, 2000.
5. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102: 1388-1393, 2000.
6. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 10: 826-837, 2010.
7. Der Sarkissian S, Marchand EL, Duguay D, Hamet P, deBlois D. Reversal of interstitial fibroblast hyperplasia via apoptosis in hypertensive rat heart with valsartan or enalapril. Cardiovasc Res 57: 775-783, 2003.
8. Der Sarkissian S, Tea BS, Touyz RM, deBlois D, Hale TM. Role of angiotensin II type 2 receptor during regression of cardiac hypertrophy in spontaneously hypertensive rats. J Am Soc Hypertens 7: 118-127, 2013.
9. Diez J, Lopez B, Gonzalez A, Querejeta R. Clinical aspects of hypertensive myocardial fibrosis. Curr Opin Cardiol 16: 328-335, 2001.
10. DiPietro LA. Wound healing: the role of the macrophage and other immune cells. Shock 4: 233-240, 1995.
11. Frangogiannis NG, Dewald O, Xia Y, Ren G, Haudek S, Leucker T, Kraemer D, Taffet G, Rollins BJ, Entman ML. Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy. Circulation 115: 584-592, 2007.
12. Guo C, Wang Y, Liang H, Zhang J. ADAMTS-1 contributes to the antifibrotic effect of captopril by accelerating the degradation of type I collagen in chronic viral myocarditis. Eur J Pharmacol 629: 104-110, 2010.
13. Hale TM, Robertson SJ, Burns KD, deBlois D. Short-term ACE inhibition confers long-term protection against target organ damage. Hypertens Res 35: 604-610, 2012.
14. Ito N, Ohishi M, Yamamoto K, Tatara Y, Shiota A, Hayashi N, Komai N, Yanagitani Y, Rakugi H, Ogihara T. Renin-angiotensin inhibition reverses advanced cardiac remodeling in aging spontaneously hypertensive rats. Am J Hypertens 20: 792-799, 2007.
15. Jiang X, Ning Q, Wang J. Angiotensin II induced differentially expressed microRNAs in adult rat cardiac fibroblasts. J Physiol Sci 63: 31-38, 2013.
16. Katoh M, Egashira K, Mitsui T, Chishima S, Takeshita A, Narita H. Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis. J Mol Cell Cardiol 32: 73-83, 2000.
17. Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, Izawa A, Takahashi Y, Masumoto J, Koyama J, Hongo M, Noda T, Nakayama J, Sagara J, Taniguchi S, Ikeda U. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 123: 594-604, 2011.
18. Koyanagi M, Egashira K, Kitamoto S, Ni W, Shimokawa H, Takeya M, Yoshimura T, Takeshita A. Role of monocyte chemoattractant protein-1 in cardiovascular remodeling induced by chronic blockade of nitric oxide synthesis. Circulation 102: 2243-2248, 2000.
19. Leuschner F, Panizzi P, Chico-Calero I, Lee WW, Ueno T, Cortez-Retamozo V, Waterman P, Gorbatov R, Marinelli B, Iwamoto Y, Chudnovskiy A, Figueiredo JL, Sosnovik DE, Pittet MJ, Swirski FK, Weissleder R, Nahrendorf M. Angiotensin-converting enzyme inhibition prevents the release of monocytes from their splenic reservoir in mice with myocardial infarction. Circ Res 107: 1364-1373, 2010.
20. Liang B, Leenen FH. Prevention of salt induced hypertension and fibrosis by angiotensin converting enzyme inhibitors in Dahl S rats. Br J Pharmacol 152: 903-914, 2007.
21. Mael-Ainin M, Abed A, Conway SJ, Dussaule JC, Chatziantoniou C. Inhibition of periostin expression protects against the development of renal inflammation and fibrosis. J Am Soc Nephrol 25: 1724-1736, 2014.
22. Meng G, Wu F, Yang L, Zhu H, Gu J, He M, Xu J. Synergistic attenuation of myocardial fibrosis in spontaneously hypertensive rats by joint treatment with benazepril and candesartan. J CardiovascPharmacol 54: 16-24, 2009.
23. Ning Q, Jiang X. Angiotensin II upregulated the expression of microRNA-224 but not microRNA-21 in adult rat cardiac fibroblasts. Biomed Rep 1: 776-780, 2013.
24. Olzinski AR, McCafferty TA, Zhao SQ, Behm DJ, Eybye ME, Maniscalco K, Bentley R, Frazier KS, Milliner CM, Mirabile RC, Coatney RW, Willette RN. Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection. Cardiovasc Res 66: 170-178, 2005.
25. Peng H, Carretero OA, Vuljaj N, Liao TD, Motivala A, Peterson EL, Rhaleb NE. Angiotensin-converting enzyme inhibitors: a new mechanism of action. Circulation 112: 2436-2445, 2005.
26. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 123: 255-278, 2009.
27. Rossini A, Zacheo A, Mocini D, Totta P, Facchiano A, Castoldi R, Sordini P, Pompilio G, Abeni D, Capogrossi MC, Germani A. HMGB1-stimulated human primary cardiac fibroblasts exert a paracrine action on human and murine cardiac stem cells. J Mol Cell Cardiol 44: 683-693, 2008.
28. Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, Narula J, Shor ES, Young JB, Hong Y. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 117: 2544-2565, 2008.
29. Stein M, Boulaksil M, Jansen JA, Herold E, Noorman M, Joles JA, van Veen TA, Houtman MJ, Engelen MA, Hauer RN, de Bakker JM, van Rijen HV. Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. Am J Physiol Heart Circ Physiol 299: H310-H321, 2010.
30. Susic D, Varagic J, Frohlich ED. Pharmacologic agents on cardiovascular mass, coronary dynamics and collagen in aged spontaneously hypertensive rats. J Hypertens 17: 1209-1215, 1999.
31. Swaney JS, Roth DM, Olson ER, Naugle JE, Meszaros JG, Insel PA. Inhibition of cardiac myofibroblast formation and collagen synthesis by activation and overexpression of adenylyl cyclase. Proc Natl Acad Sci USA 102: 437-442, 2005.
32. Tea BS, Dam TV, Moreau P, Hamet P, deBlois D. Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. Temporal regulation and spatial heterogeneity. Hypertension 34: 229-235, 1999.
33. Tomita H, Egashira K, Kubo-Inoue M, Usui M, Koyanagi M, Shimokawa H, Takeya M, Yoshimura T, Takeshita A. Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. ArteriosclerThromb Vasc Biol 18: 1456-1464, 1998.
34. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83: 1849-1865, 1991.
35. Weidenbach R, Schulz R, Gres P, Behrends M, Post H, Heusch G. Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT1-receptor antagonism. Br J Pharmacol 131: 138-144, 2000.
36. Williams SM, Golden-Mason L, Ferguson BS, Schuetze KB, Cavasin MA, Demos-Davies K, Yeager ME, Stenmark KR, McKinsey TA. Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. J Mol Cell Cardiol 67: 112-125, 2014.
37. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 93: 156-160, 1996.
38. Yu M, Zheng Y, Sun HX, Yu DJ. Inhibitory effects of enalaprilat on rat cardiac fibroblast proliferation via ROS/P38MAPK/TGF-1 signaling pathway. Molecules 17: 2738-2751, 2012.
39. Zhang Y, Huang XR, Wei LH, Chung AC, Yu CM, Lan HY. miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-/Smad3 signaling. Mol Ther 22: 974-985, 2014.